Excessive daytime sleepiness is considered as the prominent symptom in narcolepsy and
Obstructive Sleep Apnea (OSA). Pitolisant is a novel selective histamine H3 receptor …

Study Objectives: To perform a meta-analysis of the effect of wakefulness-promoting agents
(modafinil and armodafinil) in patients with residual sleepiness after CPAP therapy for …

Disclosure: The authors have received in-kind support in the form of armodafinil and
matching placebo from Teva Cephalon for a clinical trial for sleep apnea completed in the …

Obstructive sleep apnea (OSA) is a highly prevalent condition characterized by episodes of
partial or complete breath cessation during sleep that induces sleep fragmentation (SF). One …

OSA is a condition characterized by repeated episodes of complete (apnea) or partial
(hypopnea and RERA) cessation of airflow due to upper airway closure during sleep. 3 …

Adequate alertness is necessary for proper daytime functioning. Impairment of alertness or
increase in sleepiness results in suboptimal performance and adversely affects the quality of …

Study Objectives: Excessive daytime sleepiness associated with obstructive sleep apnea
affects 9%–22% of continuous positive airway pressure–treated patients. An indirect …

Abstract Objectives/Background To estimate prevalence and severity of excessive daytime
sleepiness among patients with obstructive sleep apnea (OSA) who were prescribed …

Excessive daytime sleepiness includes both an inability to stay awake during the day and a
general feeling of sleepiness. We describe different dimensions of daytime sleepiness in …

Study Objectives: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved
in the United States and European Union to treat excessive daytime sleepiness in patients …